Month: December 2020

Harju County Court approved 19 June 2020 reorganisation plan of AS Baltika. Restructuring advisor needs to submit every 6-month report to court and all creditors impacted. We will publish hereby information in the report, including financial numbers regarding 10 months, to all investors. We will draw your attention to the fact that data and numbers in the report refer to AS Baltika on a stand-alone basis and Group consolidated numbers are only in case if accordingly referred.Flavio PeriniMember of Management Board, CEOflavio.perini@baltikagroup.com  THE REPORT OF THE REORGANISATION ADVISOR ON THE FULFILMENT OF THE REORGANISATION PLANHarju County Court confirmed with 19.06.2020 ruling for civil case 2-20-4688 the reorganisation plan of AS Baltika (hereafter Baltika).In accordance with § 50 of the Reorganisation Act, the reorganisation...

19 juuni 2020 kinnitati Harju Maakohtu poolt AS Baltika saneerimiskava. Iga 6 kuu möödudes peab saneerimisnõustaja esitama aruande kohtule ja kõikidele seotud võlausaldajatele. Avalikustame siinkohal aruandes oleva informatsiooni, sh finantsnumbrid 10 kuu kohta, ka kõikidele investoritele. Pöörame lugeja tähelepanu sellele, et aruandes on andmed ja numbrid eraldi AS Baltika kohta ja Grupi konsolideeritud numbrid ainult juhul kui sellele on vastavalt viidatud.Flavio PeriniJuhatuse liige, tegevjuhtflavio.perini@baltikagroup.com   SANEERIMISNÕUSTAJA ARUANNE SANEERIMISKAVA TÄITMISE KOHTA

AB SCIENCE COMMUNICATES RESULTS FROM PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASEParis, December 18, 2020, 8.30am CETAB Science SA (NYSE Euronext – FR0010557264 – AB) today communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease, together with details on the mode of action of masitinib in Alzheimer’s disease.The presentation is available on the company’s website and is available here.Highlights of this presentation are:The mode of action of masitinib in Alzheimer’s disease (AD) is based on four targets, which may have a synergistic effect:Modulation of microglia: Microglia are involved in neuroinflammartoy processes associated with AD and masitinib modulates microglia activity through inhibition of the CSFR-1 kinase.Protection of synapses: Synapses are altered in AD and masitinib has...

AB SCIENCE PRESENTE LES RESULTATS DE L’ETUDE DE PHASE 2B/3 DU MASITINIB DANS LA MALADIE D’ALZHEIMERParis, le 18 décembre 2020, 8h30 CETAB Science SA (NYSE Euronext – FR0010557264 – AB) communique aujourd’hui les résultats de l’étude de phase 2B/3 évaluant le masitinib dans la maladie d’Alzheimer ainsi que des détails complémentaires sur le mode d’action du masitinib dans cette pathologie.La présentation de ces résultats est également disponible sur le site internet de la société ou en suivant ce lien.Les points clés de cette présentation sont les suivants :Le mode d’action du masitinib dans la maladie d’Alzheimer (MA) est basé sur quatre cibles, qui présentent un potentiel effet synergique :Modulation de la microglie : la microglie est impliquée dans les processus neuro-inflammatoires associés à la maladie d’Alzheimer...

CREDIT AGRICOLE LOIRE HAUTE LOIRESociété coopérative à capital et personnel variablesSiège social : 94, rue Bergson – 42000 SAINT ETIENNESiret 380 386 854 00018 – APE 6419 ZCaisse cotée sur  « Euronext Paris », compartiment CSt Etienne, le 18 décembre 2020La Caisse Régionale de Crédit Agricole Loire Haute Loire communique son calendrier de publication1 des résultats pour l’année 2021.  (1) Ce calendrier peut faire l’objet d’une revue annuelle et figurera dans le rapport annuel de la sociétéCe calendrier est disponible sur le site internet de la Caisse Régionale :https://www.credit-agricole.fr/ca-loirehauteloire/particulier/informations/informations-financieres.htmlInformations : www.ca-loirehauteloire.frContact relations investisseurs : Murielle Goffoz (murielle.goffoz@ca-loirehauteloire.fr)Pièce jointe20201218_ calendrier publication...

UPPSALA, SWEDEN – LIDDS AB (publ) A newly revised guideline from the Chinese National Medical Products Administration (NMPA) has extended the requirements to a full registration dossier for the conditional market approval (CMA).  LIDDS licensee Jiangxi Puheng Pharma is therefore aiming to submit the application for CMA for the prostate cancer drug candidate Liproca® Depot in China during Q1, 2021.The CMA is a faster regulatory pathway for the approval of a medicine that addresses patients’ unmet medical needs based on less comprehensive data than is normally required.“LIDDS and Jiangxi Puheng Pharma have put intensive joint efforts in compiling the dossier to be able to hand in the application. The recent request of a full registration dossier requires additional documentation that is currently being compiled by LIDDS. Even though this...

Hexatronic Group AB (publ) 556168-6360Pressmeddelande 18 december 2020Hexatronic vinner ordrar på sjökabel till ett sammanlagt värde av ca 50 MSEKHexatronic Cables & Interconnect Systems AB, ett helägt dotterbolag till Hexatronic Group AB, har på kort tid slutit flera avtal avseende fiberoptisk sjökabel. Det sammanlagda ordervärdet uppgår till ca 50 MSEK, vilket avser order från befintliga kunder i Europa och Nordamerika.Leveranserna är planerade att genomföras under 2022.Hexatronic erbjuder lösningar inom såväl sjökabel som inom hela den passiva fiberinfrastrukturen, från utformning och produktion till leverans.“Tillsammans med de ordrar vi nyligen kommunicerade har vi nu vunnit ordrar uppgående till 115 MSEK under december månad, vilket är ett starkt erkännande för vårt breda erbjudande inom sjökabel” säger Henrik Larsson Lyon,...

Hexatronic Group AB (publ) 556168-6360Press Release December 18, 2020Hexatronic wins submarine cable orders totalling approximately 50 MSEKHexatronic Cables & Interconnect Systems AB, a wholly owned subsidiary of Hexatronic Group AB, has recently signed several agreements regarding fiber optic submarine cable. The total order value amounts to approximately 50 MSEK, which is from existing customers in Europe and North America.It is planned to be delivered during 2022.Hexatronic offers system solutions in submarine cables as well as in the complete fiber optic infrastructure, from development and production to delivery.“Together with the orders we recently announced, we have now won submarine cable orders amounting to 115 MSEK during the month of December. This is a strong recognition for our broad offering in submarine cable” says...

December 18, 2020Philips to acquire BioTelemetry, Inc. for USD 72.00 per share; implied enterprise value of USD 2.8 billion (approx. EUR 2.3 billion)Acquisition is a strong fit with Philips’ strategy to transform the delivery of healthcare: combination of Philips’ leading patient monitoring position in the hospital with BioTelemetry’s leading cardiac diagnostics and monitoring position outside the hospitalWith 2019 sales of USD 439 million, BioTelemetry annually monitors over 1 million cardiac patients remotely; its portfolio includes wearable heart monitors, AI-based data analytics and servicesCombination will result in significant synergies driven by cross-selling opportunities, geographical expansion, portfolio innovation synergies, and productivity gainsBioTelemetry business is expected to deliver double-digit growth and improve its...